- Home
- ELDN vs FC Comparison
ELDN vs FC Comparison
Compare ELDN & FC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELDN | FC |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 268.7M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ELDN | FC |
|---|---|---|
| Price | $3.10 | $21.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.3M | 285.5K |
| Earning Date | 05-13-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $267,067,000.00 |
| Revenue This Year | N/A | $3.02 |
| Revenue Next Year | N/A | $3.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $11.16 |
| 52 Week High | $4.60 | $24.70 |
Technical Indicators
Market Signals| Indicator | ELDN | FC |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 71.62 |
| Support Level | $2.45 | $18.76 |
| Resistance Level | $3.17 | N/A |
| Average True Range (ATR) | 0.20 | 1.55 |
| MACD | -0.01 | 0.83 |
| Stochastic Oscillator | 70.00 | 75.29 |
Price Performance
Historical ComparisonAbout ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
About FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.